Hamid Ghanadan

Now here's an idea: Use gene editing to remove bacterial resistance to antibiotics. Then, treat with standard antibiotics. Early days, but if the tech comes to fruition this could be a game-changer for agriculture and medicine. https://okt.to/Yk45O1

8

Unicycive Therapeutics (Nasdaq: UNCY) announced FDA alignment on resolving the single manufacturing deficiency delaying approval of its novel phosphate binder Oxylanthanum Carbonate (OLC). Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/eg9U-h4f. Following constructive discussions with the FDA about resolving the single deficiency identified in June’s Complete Response Letter related to the compliance status of a third-party manufacturing vendor, Unicycive plans to resubmit its NDA for OLC by year-end. The company reported no other concerns with its preclinical, clinical, or safety data, positioning OLC for potential approval as a best-in-class phosphate binder that could reduce pill burden for dialysis patients managing hyperphosphatemia. Outcomes from the FDA meeting include: • NDA resubmission targeted before year-end 2025, potentially leading to a PDUFA date in H1 2026 • Single CRL deficiency related to third-party manufacturing vendor compliance status • Cash runway extends into 2027 with over $42 million as of September 30, 2025 • OLC offers potential best-in-class profile with lower pill burden to improve patient adherence Dr. Shalabh Gupta, MD, CEO of Unicycive, commented, “We are grateful for the highly constructive feedback and detailed meeting minutes we received from the FDA and look forward to resubmitting the NDA as we advance OLC toward potential approval. Following our interactions with the FDA, we are very encouraged about the potential for a swift resolution of the issue raised in our CRL and we believe we are now on track to resubmit our NDA before the end of the year, which could lead to a PDUFA date in the first half of 2026. See today’s press release at https://lnkd.in/eZcasbSx. Unicycive Therapeutics is a clinical-stage biotechnology company developing innovative therapies for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. Led by CEO Dr. Shalabh Gupta, MD and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/).

9

You say you 𝘥𝘰𝘯’𝘵 have a marketing budget. But you’re bleeding cash on tools, freelancers, and half-baked experiments. 𝐍𝐎 targets. 𝐍𝐎 traction. And guess what? 𝐘𝐨𝐮’𝐫𝐞 𝐬𝐭𝐢𝐥𝐥 𝐨𝐧 𝐭𝐡𝐞 𝐡𝐨𝐨𝐤 𝐟𝐨𝐫 𝐞𝐯𝐞𝐫𝐲 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧. That’s not momentum. That’s 𝐦𝐞𝐧𝐭𝐚𝐥 𝐞𝐱𝐡𝐚𝐮𝐬𝐭𝐢𝐨𝐧. 𝗬𝗼𝘂 𝗱𝗼𝗻’𝘁 𝗻𝗲𝗲𝗱 𝗺𝗼𝗿𝗲 𝗵𝘂𝘀𝘁𝗹𝗲. You need 𝙖 𝙢𝙖𝙧𝙠𝙚𝙩𝙞𝙣𝙜 𝙨𝙮𝙨𝙩𝙚𝙢 𝙬𝙞𝙩𝙝 𝙩𝙚𝙚𝙩𝙝. This week’s newsletter breaks it down → https://lnkd.in/g3XA3wvZ → How to build a marketing budget that doesn’t waste your runway → Why “we’ll figure it out later” is code for “we’re stuck” → What to do when growth is slow and resources are limited 𝐁𝐮𝐝𝐠𝐞𝐭𝐬 𝐚𝐫𝐞𝐧’𝐭 𝐣𝐮𝐬𝐭 𝐧𝐮𝐦𝐛𝐞𝐫𝐬. They’re 𝐜𝐡𝐨𝐢𝐜𝐞𝐬. 𝐏𝐫𝐢𝐨𝐫𝐢𝐭𝐢𝐞𝐬. 𝐈𝐧𝐭𝐞𝐧𝐭𝐢𝐨𝐧. If this hit a nerve, good. It means you’re ready to 𝙡𝙚𝙖𝙙 𝙬𝙞𝙩𝙝 𝙘𝙡𝙖𝙧𝙞𝙩𝙮. #FractionalCMO #MarketingStrategy #StartupMarketing #BudgetWithIntention #GrowthLeadership #ThavmaInsights #StrategyFirst

8

Pre-MS sample prep takes the most time but does not get a dedicated discussion section in a peer-reviewed publication. Anyone involved in native MS knows it takes patience, practice and bit of a luck to get great native MS Data.   Andson Biotech's DynaChip streamlines things—efficient buffer exchange, gentle sample handling, and consistent nanoESI integration. Tools like this help bring native workflows closer to the precision and reproducibility the field demands.   Worth a look if you are looking to improve your current workflow.    #NativeMS #MassSpec #Proteomics #SamplePrep #AnalyticalChemistry #nanoESI #Topdown, #CIU, #CDMS #sampleprep #MS #massspectrometry #protein #proteincomplex #membrane #StructuralBiology #Biopharmaceuticals #ProteinStability

21

Rectifying Public Health #3 Theme: Ad Knockoffs Collection: Kool Knockoffs Published: 1986 Manufacturer: BADvertising Keywords: death, Forever, Kool Spoof ads are considered subvertisements, and have been dubbed a type of “culture jamming” by Adbusters, an anti-consumerism organization that created “Joe Chemo” ads(1). Whereas advertisements are meant to enhance the image of a product , subvertising uses irony and sarcasm to criticize and mock the product. The research that has been done on other anti-tobacco campaign strategies may apply to these spoofs and give us an idea of their effectiveness. One study evaluated the reactions to spoofs by evaluating Youtube comments on ad spoofs, and it seems that most of the ads invoke humor, rather than fear, empathy, or anger (8). It is uncertain whether humor enhances the effectiveness of the ads. In focus groups, humor seems to increase the likeability of an ad, which aids in recall (2). However, likability doesn’t necessarily translate into altered behaviors, and there is a possibility that humor distracts viewers from the intended message (8). Another study showed that children were more likely to pay attention to a message that featured familiar characters (3). Using recognizable icons like Joe Camel or the Marlboro Man, two of the more popular choices for knock-off ads, will draw more attention to the ad and make people stop and look twice. But again, more attention doesn’t necessarily mean the ads are more effective in reducing smoking, especially if the ads generate negative responses. The smoking status of the viewer influences how the viewer will respond. Someone who doesn’t smoke and does not find smoking appealing with have a positive reaction to the ad and be more likely to recall the ad, while someone who smokes will be less accepting of the anti-smoking information. This may mean that spoofs may not be very effective at changing smoker’s beliefs and reducing intentions to smoke (8). - https://lnkd.in/gxhJAPP5 Image and commentary from SRITA – Stanford Research Into the Impact of Tobacco Advertising (tobacco.stanford.edu), founded by Dr. Robert Jackler in 2007. Used under fair use for educational purposes. #BigTobacco #TobaccoHistory #SRITA #PublicHealth #EndVaping #EdisonFordArtifact

2